Two firms launched initial public offerings (IPOs) last week, and neither was able to match its hopes with the reality of the market. Both priced well below the midpoints of their expected ranges.
Adesto Technologies Inc. (NASDAQ: IOTS) sold 5 million shares at $5.00 per share, well below the expected range of $10 to $12. A revised filing increased the number of shares on offer from 4.1 million to 6.0 million and fixed the price at $7 a share. But that offer did not make it out the door either. The good news is that the stock popped 18% on its first day of trading and closed the week up 19%.
The other debut last week was MyoKardia Inc. (NASDAQ: MYOK). Like Adesto, the biotech firm priced well below the midpoint of its expected range of$15 to $17 at $10 a share. Shares closed up 5% on the first day of trading and up 2% for the week.
Through the week ending October 30, IPO ETF manager Renaissance Capital reported that 154 IPOs have priced in the United States so far this year, down about 35% from a year ago. Total proceeds raised through last week equaled $28.1 billion, down about 62% compared with the same period in 2014. Of the 154 IPOs that have gone off this year, 72 have come from the health care sector. Last year’s IPO total came in at $85.2 billion, the highest total in the past 10 years. Renaissance Capital does not include “best efforts” or blank-check companies in its totals.
There are four IPOs on the calendar for the week beginning November 2, including a bank, two biotech firms and a technology firm.
First Guaranty Bancshares is a Louisiana corporation and bank holding company with 21 locations in the state. The offering is a transplant from the OTC pink sheets, according to the S-1/A filing. The company plans to offer 750,000 shares at $21 per share, raising $15.8 million at a market cap of $147 million. Sole bookrunner for the offering is Sandler O’Neill. The IPO is listed only for the week of November 2 and shares will trade on the Nasdaq under the ticker symbol FGBI.
Kura Oncology is a clinical stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. This is a transplant offering from the OTCQB venture marketplace. The company plans to offer 3.8 million shares at a fixed price of $16 a share, raising $60 million at an implied market cap of about $293 million. Joint bookrunners for the offering are Citigroup and Leerink Partners. Co-managers are JMP Securities and Oppenheimer. Shares are expected to price on Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol KURA.
GenSight Biologics is a Paris-based a clinical-stage biotechnology company developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and, in the future, of the central nervous system. The company plans to offer 4.7 million shares in an expected price range of $13 to $15, raising $65 million at an implied market cap of $255.6 million. Joint bookrunners for the offering are Leerink Partners, Evercore ISI and Canaccord Genuity. Shares are expected to price Thursday and begin trading Friday on the Nasdaq under the ticker symbol GNST.
Xtera Communications is a developer of high-capacity optical transport products. The company plans to offer 5.5 million shares in an IPO price range of $9 to $11 to raise $55 million at an implied market cap of $176 million. Joint bookrunners for the offering are Needham, Cowen and BMO Capital Markets. Shares are expected to price Thursday and begin trading Friday on the Nasdaq under the ticker symbol XCOM.